Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Abstract | Full HTML Article | PDF ecancer 13 967 / https://doi.org/10.3332/ecancer.2019.967

Clinical Study

Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model

Introduction: We evaluated overall survival (OS) benefit of complete metastasectomy (CM) in metastatic renal cell carcinoma (mRCC) using a propensity score-matched (PSM) analysis to balance groups by age, gender and by the International Metastatic RCC Database Consortium prognostic model (IMDC).

Methods: We included patients (pts) treated at the AC Camargo Cancer Center between 2007 and 2016. Pairs were matched by age, gender and IMDC. Kaplan–Meier survival estimates and Cox proportional hazard models were used to evaluate OS on CM and no-CM group.

Results: We found 116 pts with clear cell mRCC. After PSM, the number was reduced to 74 (37 CM, 37 no-CM). The median OS for CM and no-CM was 98.3 months and 40.5 months, respectively (hazard ratio 0.24 95%CI 0.11–0.53 p < 0.001). The OS benefit of CM was confirmed on favourable and intermediate IMDC but was absent on poor IMDC. The CM group received less systemic therapy than the no-CM group. Ten pts in the CM group still have no evidence of disease (NED).

Conclusion: After matching for age, gender and IMDC, we found CM impacts on OS and also diminishes the need for systemic treatment. Survival benefit was confirmed for favourable/intermediate IMDC but not for the poor IMDC prognostic model. Further studies correlating IMDC and metastasectomy are needed to guide clinical decision-making.

Keywords: metastasectomy, clear cell renal cell carcinoma, targeted therapy, propensity score matching

Loading Article Metrics ... Please wait

Related articles

Short Communication: Elimination of cervical cancer: challenges for developing countries

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.975

Review: Barriers to the composition and implementation of advance directives in oncology: a literature review

Abstract | Full Article | PDF Published: 12 Nov 2019 / https://doi.org/10.3332/ecancer.2019.974

Research: Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?

Abstract | Full Article | PDF Published: 04 Nov 2019 / https://doi.org/10.3332/ecancer.2019.973

Case Report: Common B-cell acute lymphoblastic leukaemia in a 70-year-old woman presenting 2 years after carboplatin-taxane radiotherapy for endometrial cancer

Abstract | Full Article | PDF Published: 29 Oct 2019 / https://doi.org/10.3332/ecancer.2019.972

Clinical Study: Pathological upgrading and upstaging at radical prostatectomy in Jamaican men with low-risk prostate cancer

Abstract | Full Article | PDF Published: 29 Oct 2019 / https://doi.org/10.3332/ecancer.2019.971

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation